Patient Capital Goes Big on Precigen with 10.2 Million‑Share Bet

In a strategic move, investment firm Patient Capital Management LLC disclosed acquiring approximately 10.2 million shares of biotech company Precigen, Inc. (NASDAQ: PGEN). The stake puts the firm among the largest shareholders and signals strong conviction in Precigen’s pipeline of gene- and cell‑therapy assets. Precigen, which focuses on advancing treatments for infectious diseases, auto‑immune conditions and oncology through synthetic biology platforms, has been gaining attention following regulatory progress and recent clinical milestones. The new investment injects further investor confidence into the company’s prospects and may mark a pivotal moment in its capital‑markets strategy. Meanwhile, given biotech volatility and high cash burn typical of the sector, observers caution that success still hinges on execution of clinical programs and regulatory approvals. #Precigen #PatientCapital #BiotechInvesting #GeneTherapy #SlimScan #GrowthStocks #CANSLIM